Results 121 to 130 of about 35,907 (256)

NTAQ1 Promotes Hepatocellular Carcinoma Growth by Facilitating the Protein Degradation of the Tumor Suppressor PRDM2

Cancer Science, EarlyView.
Copy number variation analysis in The Cancer Genome Atlas identified NTAQ1 as a potential driver of HCC progression. NTAQ1 accelerates tumor growth by promoting the degradation of the tumor suppressor protein PRDM2, thereby impairing DNA repair and suppressing apoptosis. These findings indicate that NTAQ1 could be a valuable target for the treatment of
Tomohiko Ikehara, Hajime Otsu, Taro Tobo, Kiyotaka Hosoda, Tadashi Abe, Masahiro Hashimoto, Yusuke Nakano, Katsushi Dairaku, Yuya Ono, Yuki Miyata, Chihiro Matsumoto, Takanari Tatsumi, Satoshi Higuchi, Takashi Ofuchi, Akinori Tsujimoto, Yuki Ando, Qingjiang Hu, Yusuke Yonemura, Akira Shimizu, Takaaki Masuda, Yuji Soejima, Koshi Mimori   +21 more
wiley   +1 more source

Risk-reducing mastectomy and salpingo-oophorectomy in unaffected BRCA mutation carriers: uptake and timing

, 2010
Udgivelsesdato: 2010-AprOnce female carriers of a BRCA mutation are identified they have to make decisions on risk management. The aim of this study is to outline the uptake of risk-reducing surgery in the Danish population of BRCA mutation positive ...
Kølvraa, Steen, Crüger, D, Andersen, M K, Sunde, L, Brøndum-Nielsen, K, Gerdes, A-M, Waldstrøm, M, Skytte, A-B, Gerdes, Anne-Marie Axø, Kølvraa, S   +9 more
core   +2 more sources

The WHO Classification of Genetic Tumour Syndromes: Considerations for Genetics

Clinical Genetics, EarlyView.
The WHO Classification of Tumours underpins the diagnosis of neoplastic conditions. The new WHO classification of genetic tumour syndromes (GTS) provides international standards for their diagnosis. This diagram highlights the chromosomal distribution of the genes involved in the GTS covered in this classification.
Ian A. Cree, Mark J. Arends, Joseph D. Khoury, Erika R. E. Denton, Anthony J. Gill, Alexander J. Lazar, Ian M. Frayling, Stefan M. Pfister, Mark A. Rubin, Katia R. M. Leite, Raymond Dalgleish, Elspeth A. Bruford, Sharon E. Plon, Ada Hamosh, Michael Francis Walsh, Gabrielle Goldman‐Lévy, Harshima Wijesinghe, William D. Foulkes, Dilani Lokuhetty   +18 more
wiley   +1 more source

Impact of BRCA1/2 germline mutation on the incidence of second primary cancer following postoperative radiotherapy in patients with triple-negative breast cancer

Zhongguo aizheng zazhi
Background and purpose: BRCA1/2 plays an important role in maintaining the genome stability. Whether BRCA1/2 germline mutation could increase the tumor sensitivity to radiotherapy, thereby inducing secondary primary cancer after radiotherapy is unclear ...
Xiaoyu HU, Yuwen CAI, Fugui YE, Zhimin SHAO, Weigang HU, Keda YU   +5 more
doaj  

The Role of SAMHD1 in Viral Resistance and Transduction Efficiency Challenges in Pediatric Hematological Malignancies: Mechanistic Insights and Clinical Perspectives

European Journal of Haematology, EarlyView.
SAMHD1 regulates intracellular dNTP pools, influencing lentiviral transduction, gene therapy efficiency, and disease progression in pediatric hematological malignancies. Integrated bioinformatics and targeted strategies, including CRISPR and pharmacological inhibition, highlight its therapeutic potential.
Waseem Alzamzami
wiley   +1 more source

The cost-effectiveness of germline BRCA testing in metastatic prostate cancer followed by cascade testing of first-degree relatives of mutation carriers

OBJECTIVES: Metastatic prostate cancer (mPCa) patients with BRCA mutations benefit from targeted treatments (e.g., olaparib). Additionally, family members of affected patients have increased risk of hereditary cancers and benefit from early detection and
Scuffham, Paul, Smith, David P, Tuffaha, Haitham, Horvath, Lisa, Roberts, Matthew J, Edmunds, Kim, Teppala, Srinivas, Fairbairn, David   +7 more
core   +1 more source

Physiological media and oxygen levels modulate cancer hallmarks in cultured breast cancer cells

The FEBS Journal, EarlyView.
MCF7 breast cancer cells were cultured in standard conditions (18% O2 and DMEM) and physiological conditions (5% O2 and Plasmax, a medium modeled after the human plasma metabolome). A combined transcriptomic and proteomic approach was used to identify gene expression signatures at the mRNA and protein levels upstream of functional enrichment analyses ...
Jacob E. Wiebe, Ricardo Alva, Fereshteh Moradi, Sarah Alderman, Ping Liang, Jeffrey A. Stuart   +5 more
wiley   +1 more source

Risk of breast cancer (BC) after BRCA-mutation associated ovarian cancer (BRCA-OC): Memorial Sloan-Kettering Cancer Center (MSKCC) experience.

, 2011
Risk of breast cancer (BC) after BRCA-mutation associated ovarian cancer (BRCA-OC): Memorial Sloan-Kettering Cancer Center (MSKCC ...
ME Robson (14461866), KL Jhaveri (14538107), ND Kauff (14538113), S Patil (12148251), J Bhatia (7690535), C Hudis (13470700), M Khasraw (12897953), K Offit (7690526), ZK Stadler (14538110)   +8 more
core  

FOXA1 is a highly sensitive diagnostic marker for prostate cancer including small cell carcinoma of the prostate

Histopathology, EarlyView.
FOXA1 is a highly sensitive diagnostic marker for prostate cancer. Besides prostatic adenocarcinoma, it is also expressed in 57%–80% of metastatic or primary prostatic small cell carcinomas, which lose traditional prostatic markers including NKX3.1. Although it is less specific than NKX3.1, it can serve as a valuable adjunct for confirming prostatic ...
Jianping Zhao, Jun Yao, Hossein Hosseini, Ezra Baraban, Ruihe Lin, Charles C. Guo, Lei Huo, Wei Lu, Khaja Khan, Shufang Wang, Luisa Maren Solis Soto, Qingqing Ding   +11 more
wiley   +1 more source

An Update on Early‐Onset Breast Cancer: Incidence, Risk Factors, Genetic Testing, and Treatment

Computational and Systems Oncology, Volume 6, Issue 1, December 2026.
ABSTRACT Early‐onset breast cancer presents in patients typically under the age of 40, while very early‐onset breast cancer is usually viewed as breast cancer occurring before the age of 35. Early‐onset breast cancer demonstrates specific molecular properties and has worse outcomes compared to its late‐onset breast cancer counterpart.
Leila Jahangiri
wiley   +1 more source